All lobbying filings

MEHLMAN CONSULTING, INC.

Lobbying for THE CAMPAIGN FOR SUSTAINABLE RX PRICING · A coalition of organizations working on market-based solutions to drug pricing.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $90,000.00 income · posted Apr 17, 2025

Official filing document

Bills named in this filing 9

S 229
DTC Act of 2025
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1302
Increasing Transparency in Generic Drug Applications Act
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 1095
Stop STALLING Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 43
Skinny Labels, Big Savings Act

Lobbying activity 3

Medicare/Medicaid

Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act.

Pharmacy

Prescription drug pricing issues. H.R. 1843/S. 1302 - Increasing Transparency in Generic Drug Applications Act.

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.